(BMC Ophthalmol[TA])
5,785 results
  • Early outcomes of switching from bevacizumab to aflibercept-jbvf in exudative macular diseases: a real-world study. [Journal Article]
    BMC Ophthalmol. 2026 Oct 28; 26(1).Horozoglu Ceran T, Beyatli S, Dogan MBO
  • CONCLUSIONS: Administration of aflibercept-jbvf following three monthly bevacizumab injections was temporally associated with a statistically significant but modest very early reduction in CST at 4 weeks in this heterogeneous cohort of exudative macular diseases. Because DME, neovascular AMD-related MNV, and RVO represent biologically and clinically distinct disease entities, the pooled findings should be interpreted as descriptive cohort-level estimates within this shared treatment pathway rather than as evidence of a uniform treatment effect across these conditions. A small numerical trend toward BCVA improvement was observed, but the change was not statistically significant in either the unadjusted or GEE-adjusted analysis. Because this was a single-arm study without a comparator group, the observed anatomical change cannot be attributed specifically to aflibercept-jbvf and may partly reflect a delayed or cumulative response to prior bevacizumab, regression to the mean, or natural variability in retinal thickness. Diagnosis-specific findings were exploratory, and the 4-week endpoint does not provide information regarding durability of response or longer-term treatment burden.